Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Combination therapy group:Xiyanping injection+ conventional treatment
Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old; 2. Meet the diagnostic criteria for confirmed cases in the diagnosis and treatment plan of new coronavirus-infected pneumonia (trial version 5); and the clinical symptoms before admission or screening must meet the following conditions: Fever (armpit temperature >=37.3 degree C, or mouth temperature >=38.0 degree C, or anal or ear temperature >=38.6 degree C) 24 beats / min or cough (at least one of the two); 3. Confirmed 2019-nCoV infection by Laboratory inspection (RT-PCR); 4. Have not previously received treatment or experimental treatment for COVID-19. Patients who have been treated with proprietary Chinese medicine or lopinavir / ritonavir tablets for less than 3 days can be enrolled; 5. Subjects volunteerly participate in this study and agree to sign informed consent; 6. According to the researcher's judgment, the subject / legal guardian is considered reliable and able to comply with this plan, visit plan and medication arrangement.
Exclusion criteria
Exclusion criteria: 1. Allergic constitution (persons who are allergic to more than 2 kinds of substances), people who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test drugs; 2. Patients who have participated in other clinical trials in the past 3 months; 3. Patients not suitable for the clinical trials judged by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical recovery time; | — |
Secondary
| Measure | Time frame |
|---|---|
| fever; | — |
Countries
China
Contacts
Public ContactHongzhou Lu
Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Outcome results
None listed